World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
115
Citations
58941
World Ranking
4481
National Ranking
168

Egbert F. Smit publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Egbert F. Smit sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 782 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Egbert F. Smit D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Egbert F. Smit sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 115 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Egbert F. Smit is affiliated with VU University Medical Center in the Netherlands and has a research focus primarily within the field of Medicine, with notable expertise in pulmonary and respiratory medicine, oncology, and cancer research.

Their work covers key areas such as lung cancer treatments and mutations, lung cancer diagnosis and treatment, colorectal cancer studies, cancer immunotherapy and biomarkers, as well as molecular biology and cancer genomics.

Frequent publication venues for Smit include the following:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Lung Cancer
  • Cancer Research

Collaborations are an important aspect of their research, with frequent coauthors being:

  • Enriqueta Felip
  • Anne-Marie C. Dingemans
  • Kim Monkhorst
  • Adrianus J. de Langen
  • Vincent van der Noort

Recent publications illustrate a focus on oncogene-addicted and non-oncogene-addicted metastatic non-small-cell lung cancer, as well as targeted treatments and mutations. Notable papers include:

  • "Capmatinib in MET Exon 14-Mutated or MET -Amplified Non-Small-Cell Lung Cancer," 2020, New England Journal of Medicine
  • "Trastuzumab Deruxtecan in HER2 -Mutant Non-Small-Cell Lung Cancer," 2021, New England Journal of Medicine
  • "Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations," 2020, New England Journal of Medicine
  • "Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology

Their publications have garnered significant citations, with some papers cited over 900 times, reflecting the relevance of their research within the field.

Best Publications

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George

  • Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

    Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran

  • Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

    David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres

  • Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial.

    Harm Van Tinteren;Otto S. Hoekstra;Egbert F. Smit;Jan H.A.M. Van Den Bergh

  • Long-term expanding human airway organoids for disease modeling

    Norman Sachs;Angelos Papaspyropoulos;Domenique D. Zomer-van Ommen;Inha Heo

  • Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

    Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer

  • Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

    Krijn K Dijkstra;Chiara M Cattaneo;Fleur Weeber;Myriam Chalabi

  • Pan-cancer whole-genome analyses of metastatic solid tumours

    Peter Priestley;Jonathan Baber;Martijn P. Lolkema;Neeltje Steeghs

  • RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics

    Myron G. Best;Nik Sol;Irsan Kooi;Jihane Tannous

  • Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer

    Jan P. van Meerbeeck;Gijs W. P. M. Kramer;Paul E. Y. Van Schil;Catherine Legrand

  • A genomics-based classification of human lung tumors

    Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik;Enriqueta Felip;Remi Veillon;Hiroshi Sakai

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer

    Frank J. Lagerwaard;Cornelis J.A. Haasbeek;Egbert F. Smit;Ben J. Slotman

  • Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

    Dong-Wan Kim;Dong-Wan Kim;Marcello Tiseo;Myung-Ju Ahn;Karen L Reckamp

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

    Jonathan W Goldman;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

    Egbert F. Smit;Jan P.A.M. van Meerbeeck;Pilar Lianes;Channa Debruyne

Frequent Co-Authors

Pieter E. Postmus
Pieter E. Postmus Leiden University Medical Center
Harry J.M. Groen
Harry J.M. Groen University Medical Center Groningen
Suresh Senan
Suresh Senan University of Amsterdam
Otto S. Hoekstra
Otto S. Hoekstra Amsterdam UMC
Anne-Marie C. Dingemans
Anne-Marie C. Dingemans Erasmus University Rotterdam
Ronald Boellaard
Ronald Boellaard Amsterdam UMC
Adriaan A. Lammertsma
Adriaan A. Lammertsma VU University Medical Center
Peter J.F. Snijders
Peter J.F. Snijders Vrije Universiteit Amsterdam
Giuseppe Giaccone
Giuseppe Giaccone Cornell University
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, a wide spectrum of related online degrees and flexible career pathways are available. These programs make it possible to advance your education and professional goals, whether you’re new to the field or seeking specialization.

Healthcare administration is a growing area, and pursuing a cahme accredited Master’s in Health Administration ensures a high standard of curriculum and credibility for leadership roles. Alternatively, those passionate about public health and wellness can consider an online nutrition degree to enter fields like dietetics or health coaching.

Registered nurses looking to advance their careers can benefit from the best online rn to bsn programs without clinical requirements, offering a more streamlined path to obtain a bachelor’s degree. Additionally, experienced nurses can fast-track their education by enrolling in the shortest msn to dnp program to achieve a Doctor of Nursing Practice degree more quickly.

Whether you seek clinical practice or administrative leadership, these online degrees provide flexible options to expand your expertise and broaden your career opportunities in healthcare.

Best Scientists Citing Egbert F. Smit

Trending Scientists

Recently Published Articles